Literature DB >> 26022721

Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients.

Chloé Bourguignon1, Leïla Chenine2, Anne Sophie Bargnoux1,3, Hélène Leray-Moragues2, Bernard Canaud4,5, Jean-Paul Cristol6,7,8,9, Marion Morena1,3,4.   

Abstract

BACKGROUND/AIMS: Serum free light chain (FLC) levels are correlated with chronic kidney disease (CKD) stages and are highest in patients on hemodialysis (HD). Aim of this study was to assess the FLC removal efficiency of Elisio™-210H dialyzer using either high-flux HD or on line high efficiency hemodiafiltration (HDF) modalities in CKD-5D patients.
METHODS: In this prospective and comparative study, 20 CKD-5D patients free from multiple myeloma were randomized in two groups: HD versus on line HDF. All patients were dialyzed with Elisio™-210H dialyzer. Serum samples were collected before and after the midweek dialysis session, before randomization and at the end of the study to measure κ and λ FLC concentrations. Reduction ratios were corrected for net ultrafiltration.
RESULTS: For both HD and HDF mode, κ and λ FLC concentrations were significantly lower after dialysis than before but median reductions in κ and λ FLC levels were significantly higher in HDF versus HD groups (κ 73.5 vs. 65.5 %, p = 0.04 and λ 51.0 vs. 36.6 %, p = 0.07). After dialysis, all κ/λ ratio values were between 0.26 and 1.65 which is the reference range described in subjects with normal kidney function, for both HD and HDF groups (median κ/λ ratios were 0.80 [0.47-1.22] and 0.67 [0.50-0.79] respectively).
CONCLUSION: This study shows the superiority of on line HDF compared with HD to remove both κ and λ FLC. Moreover, all post-dialysis κ/λ ratios reached normal reference range.

Entities:  

Keywords:  CKD; HDF; Internal convection HD; Serum free light chain removal

Mesh:

Substances:

Year:  2015        PMID: 26022721     DOI: 10.1007/s40620-015-0207-z

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  16 in total

1.  Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application?

Authors:  Richard A Ward
Journal:  J Am Soc Nephrol       Date:  2005-06-23       Impact factor: 10.121

2.  Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Authors:  Colin A Hutchison; Paul Cockwell; Steven Reid; Katie Chandler; Graham P Mead; John Harrison; John Hattersley; Neil D Evans; Mike J Chappell; Mark Cook; Hermann Goehl; Markus Storr; Arthur R Bradwell
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

3.  Increased concentrations of free light chain lambda in sera from chronic hemodialysis patients.

Authors:  K Wakasugi; M Sasaki; M Suzuki; N Azuma; T Nobuto
Journal:  Biomater Artif Cells Immobilization Biotechnol       Date:  1991

4.  Single compartment models for evaluating beta 2-microglobulin clearance during hemodialysis.

Authors:  J K Leypoldt; A K Cheung; R B Deeter
Journal:  ASAIO J       Date:  1997 Nov-Dec       Impact factor: 2.872

5.  A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR).

Authors:  Sonia Pasquali; Francesco Iannuzzella; Mattia Corradini; Silvia Mattei; Achiropita Bovino; Alfredo Stefani; Giuseppe Palladino; Marialuisa Caiazzo
Journal:  J Nephrol       Date:  2014-08-23       Impact factor: 3.902

6.  Comparison between on-line high-efficiency hemodiafiltration and conventional high-flux hemodialysis for polyclonal free light chain removal.

Authors:  Thomas Lamy; Patrick Henri; Thierry Lobbedez; Elisabeth Comby; Jean-Philippe Ryckelynck; Maxence Ficheux
Journal:  Blood Purif       Date:  2014-03-01       Impact factor: 2.614

7.  Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients.

Authors:  Gerald Cohen; Michael Rudnicki; Sabine Schmaldienst; Walter H Hörl
Journal:  Nephrol Dial Transplant       Date:  2002-05       Impact factor: 5.992

8.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

9.  Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease.

Authors:  Colin A Hutchison; Anne Burmeister; Stephen J Harding; Kolitha Basnayake; Hannah Church; Mark D Jesky; Katie White; Clara E Green; Stephanie J Stringer; Paul Bassett; Charles J Ferro; Paul Cockwell
Journal:  Mayo Clin Proc       Date:  2014-05       Impact factor: 7.616

10.  Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Authors:  Colin A Hutchison; Tim Plant; Mark Drayson; Paul Cockwell; Melpomeni Kountouri; Kolitha Basnayake; Stephen Harding; Arthur R Bradwell; Graham Mead
Journal:  BMC Nephrol       Date:  2008-09-22       Impact factor: 2.388

View more
  7 in total

Review 1.  Light Chain Cast Nephropathy in Multiple Myeloma: Prevalence, Impact and Management Challenges.

Authors:  Paolo Menè; Antonella Stoppacciaro; Silvia Lai; Francescaromana Festuccia
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-05-13

2.  Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers.

Authors:  Gabriele Donati; Maria Ilaria Moretti; Olga Baraldi; Alessandra Spazzoli; Irene Capelli; Giorgia Comai; Antonio Marchetti; Maria Sarma; Rita Mancini; Gaetano La Manna
Journal:  BMC Nephrol       Date:  2016-11-25       Impact factor: 2.388

3.  Performance of hemodialysis with novel medium cut-off dialyzers.

Authors:  Alexander H Kirsch; Raphael Lyko; Lars-Göran Nilsson; Werner Beck; Michael Amdahl; Petra Lechner; Andreas Schneider; Christoph Wanner; Alexander R Rosenkranz; Detlef H Krieter
Journal:  Nephrol Dial Transplant       Date:  2017-01-01       Impact factor: 5.992

4.  SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.

Authors:  Joan Perelló; M Gómez; M D Ferrer; N Y Rodríguez; C Salcedo; J M Buades; M M Pérez; J V Torregrosa; E Martín; F Maduell
Journal:  J Nephrol       Date:  2018-01-19       Impact factor: 3.902

5.  Randomized controlled trial of medium cut-off versus high-flux dialyzers on quality of life outcomes in maintenance hemodialysis patients.

Authors:  Jeong-Hoon Lim; Yeongwoo Park; Ju-Min Yook; Soon-Youn Choi; Hee-Yeon Jung; Ji-Young Choi; Sun-Hee Park; Chan-Duck Kim; Yong-Lim Kim; Jang-Hee Cho
Journal:  Sci Rep       Date:  2020-05-08       Impact factor: 4.379

6.  Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.

Authors:  Ola Landgren; Sigurdur Yngvi Kristinsson; Thorir Einarsson Long; Olafur Skuli Indridason; Runolfur Palsson; Sæmundur Rognvaldsson; Thorvardur Jon Love; Sigrun Thorsteinsdottir; Ingigerdur Solveig Sverrisdottir; Brynjar Vidarsson; Pall Torfi Onundarson; Bjarni Agnar Agnarsson; Margret Sigurdardottir; Ingunn Thorsteinsdottir; Isleifur Olafsson; Asdis Rosa Thordardottir; Elias Eythorsson; Asbjorn Jonsson; Gauti Gislason; Andri Olafsson; Hlif Steingrimsdottir; Malin Hultcrantz; Brian G M Durie; Stephen Harding
Journal:  Blood Cancer J       Date:  2022-09-14       Impact factor: 9.812

7.  Randomised trial on clinical performances and biocompatibility of four high-flux hemodialyzers in two mode treatments: hemodialysis vs post dilution hemodiafiltration.

Authors:  Marion Morena; Caroline Creput; Mouloud Bouzernidj; Annie Rodriguez; Lotfi Chalabi; Bruno Seigneuric; Céline Lauret; Anne-Sophie Bargnoux; Anne-Marie Dupuy; Jean-Paul Cristol
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.